Abbott India Limited announced that upon recommendation of the Nomination and Remuneration Committee and the Audit Committee, the Board of Directors at its Meeting held on April 18, 2025, approved the appointment of Ms. Maithilee Mistry as the Chief Financial Officer of the Company with effect from May 6, 2025. Maithilee Mistry is a seasoned finance professional having an extensive work experience spanning more than 25 years, having held leadership roles in various Multinational companies. Previously Maithilee held a role of CFO for Sanofi Consumer Healthcare India Limited.
Prior to that, she worked with Dow chemical in USA as global Funding Director, responsible for all aspects of corporate funding and banking relations. Before relocating to USA, she was Finance Director for Dow Chemical, India subcontinent region. Maithilee has also served as Board member in various companies including a public listed entity and other joint ventures in India.
Before Joining Dow, she has also held leadership positions with Omya and Cognis, European multinational companies, leading teams in India and Southwest Asia with responsibilities for Finance, HR, Legal and IT. She is a qualified Chartered Accountant who started her career with Deloitte (India) as a member of statutory audit team. Ms. Maithilee Mistry is not related to any of the Directors/Key Managerial Personnel/Senior Management of the Company.
Abbott India Limited is an India-based pharmaceutical company. The Company is involved in product development, manufacturing, sales, and customer service. It distributes products and solutions in multiple therapeutic categories, such as women's health, gastroenterology, cardiology, metabolic disorders and primary care. It operates in a single reportable business segment, which is Pharmaceuticals. The Company’s products include Arachitol Nano, Digeraft, Influvac, Colospa, Duphalac, Librax, Creon, Duphaston, Prothiaden, Cremaffin, Duvadilan, Thyronorm, Cremaffin Plus, Ganaton, Udiliv, Digene, Heptral, Vertin, Zolfresh, Citrosoda UTI, Digene Insta On The Go, Digeraft tablet, Duphaston OD, Pneumoshield 14, Prothiaden Neu, Vonefi, Levesam, and LOBATE M Skin Cream, among others. The Company sells its products through independent distributors primarily within India.
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
-
Quality
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
